Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Sidney Kimmel Comprehensive Cancer Center.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Bracco Diagnostics, Inc
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00539253
First received: October 2, 2007
Last updated: February 7, 2012
Last verified: February 2012

October 2, 2007
February 7, 2012
September 2007
December 2012   (final data collection date for primary outcome measure)
The primary outcome measurement is agreement of tumor necrosis using triple-phase MultiHance-enhanced MRI, with the percent necrosis seen in patients following surgery or tissue biopsy. [ Time Frame: 2007-2010 ] [ Designated as safety issue: No ]
The primary outcome measurement is agreement of tumor necrosis using triple-phase MultiHance-enhanced MRI, with the percent necrosis seen in patients following surgery or tissue biopsy.
Complete list of historical versions of study NCT00539253 on ClinicalTrials.gov Archive Site
To determine if some combination of the MRI enhancement in the three phases is a better predictor of necrosis compared to enhancement in a single phase. [ Time Frame: 2007-2010 ] [ Designated as safety issue: No ]
To determine if some combination of the MRI enhancement in the three phases is a better predictor of necrosis compared to enhancement in a single phase.
Not Provided
Not Provided
 
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization Using Functional Triple-Phase MultiHance-Enhanced MRI

This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is believed that using MultiHance may be able to help doctors tell normal liver cells apart from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve the way patients with hepatocellular carcinoma are managed clinically.

We hypothesize that the Multi-Hance contrast material will provide better image definition of treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast agents.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Hepatocellular Carcinoma
Drug: gadobenate dimeglumine (MultiHance)
The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
Other Name: MultiHance
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
25
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
  • INR<1.4
  • Platelet count > 80,000

Exclusion Criteria:

  • Contraindications to TACE procedure
  • Unable to have an MRI Scan
  • Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
  • Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
  • Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
  • Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min)
  • Pregnancy
Both
18 Years to 80 Years
No
Contact: Margaret Mensa, RN 410 614 1608 mmensa2@jhmi.edu
Contact: Ihab Kamel, MD, PhD 410 955-4567 ikamel@jhmi.edu
United States
 
NCT00539253
J06108, NA_00003943
No
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Bracco Diagnostics, Inc
Principal Investigator: Ihab Kamel The Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP